| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Biomarin Pharmaceutical Inc.'s insiders have reduced their positions by a net 17,557 shares worth roughly $1.2M.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 214.6K | $11.95M | - | |
| CFO | 123.3K | $6.86M | - | |
| VP | 84.1K | $4.68M | - | |
| VP | 61.0K | $3.40M | - | |
| Dir | 49.4K | $2.75M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Apr 1, 2019 | Daniel K Spiegelman59 | EVP, Chief Financial Officer | Sell | 13,473 | $89.00 | $1,199,097.00 | -22.1% | |
| Mar 27, 2019 | Daniel K Spiegelman59 | EVP, Chief Financial Officer | Sell | 100 | $90.00 | $9,000.00 | -0.2% | |
| Mar 27, 2019 | V Bryan Lawlis53 | Director | Sale+OE | 2,150 | $89.76 | $192,984.00 | -10.1% | |
| Mar 26, 2019 | Jeffrey Robert Ajer58 | EVP, Chief Commercial Officer | Sell | 3,656 | $89.18 | $326,024.90 | -7.2% | |
| Mar 25, 2019 | George Eric Davis65 | EVP, General Counsel | Sell | 3,363 | $87.86 | $295,473.18 | -4.5% | |
| Mar 25, 2019 | Henry J Fuchs | President, Worldwide R& D | Sell | 5,932 | $87.86 | $521,185.52 | -4.5% | |
| Mar 25, 2019 | Jean Jacques Bienaime68 | Chief Executive Officer | Sale+OE | 4,000 | $87.86 | $351,440.00 | -1.2% | |
| Mar 21, 2019 | Jeffrey Robert Ajer58 | EVP, Chief Commercial Officer | Sell | 4,519 | $89.98 | $406,633.95 | -7.6% | |
| Mar 19, 2019 | Jeffrey Robert Ajer58 | EVP, Chief Commercial Officer | Sell | 3,728 | $93.07 | $346,964.96 | -5.9% | |
| Mar 19, 2019 | George Eric Davis65 | EVP, General Counsel | Sell | 7,907 | $93.92 | $742,625.44 | -9.1% |